It has been suggested that metastasis-initiating cells gain a foothold in bone by homing to a metastastatic microenvironment (or 'niche'). Whereas the precise nature of this niche remains to be established, it is likely to contain bone cell populations including osteoblasts and osteoclasts. In the mouse tibia, the distribution of osteoblasts on endocortical bone surfaces is non-uniform and we hypothesize that studying co-localization of individual tumour cells with resident cell populations will reveal the identity of critical cellular components of the niche. In this study, we have mapped the distribution of three human prostate cancer cell lines (PC3-NW1, LN-CaP, and C4 2B4) colonising the tibias of athymic mice following intracardiac injection and evaluated their interaction with potential metastatic niches. Prostate cancer cells labelled with the fluorescent cell membrane dye (Vybrant DiD) were found by twophoton microscopy to be engrafted in the tibiae in close proximity (~40 m) to bone surfaces and 70% more cancer cells were detected in the lateral compared to the medial endocortical bone regions. This was associated with a 5-fold higher number of osteoblasts and 7-fold higher bone formation rate on the lateral endocortical bone surface compared to the medial side. By disrupting cellular interactions mediated by the chemokine (C-X-C motif) receptor 4 (CXCR4)/chemokine ligand 12 (CXCL12) axis with the CXCR4 inhibitor AMD3100, the preferential homing pattern of prostate cancer cells to osteoblast-rich bone surfaces was disrupted. In this study, we map the location of prostate cancer cells that home to endocortical regions in bone and our data demonstrate that homing of prostate cancer cells is associated with the presence and activity of osteoblast lineage cells, and suggest that therapies targeting osteoblast niches should be considered to prevent development of incurable prostate cancer bone metastases.
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Abstract:
It has been suggested that metastasis-initiating cells gain a foothold in bone by homing to a metastastatic microenvironment (or 'niche'). Whereas the precise nature of this niche remains to be established, it is likely to contain bone cell populations including osteoblasts and osteoclasts. In the mouse tibia, the distribution of osteoblasts on endocortical bone surfaces is non-uniform and we hypothesize that studying co-localization of individual tumour cells with resident cell populations will reveal the identity of critical cellular components of the niche. In this study, we have mapped the distribution of three human prostate cancer cell lines (PC3-NW1, LN-CaP, and C4 2B4) colonising the tibias of athymic mice following intracardiac injection and evaluated their interaction with potential metastatic niches. Prostate cancer cells labelled with the fluorescent cell membrane dye (Vybrant DiD) were found by twophoton microscopy to be engrafted in the tibiae in close proximity (~40 m) to bone surfaces and 70% more cancer cells were detected in the lateral compared to the medial endocortical bone regions. This was associated with a 5-fold higher number of osteoblasts and 7-fold higher bone formation rate on the lateral endocortical bone surface compared to the medial side. By disrupting cellular interactions mediated by the chemokine (C-X-C motif) receptor 4 (CXCR4)/chemokine ligand 12 (CXCL12) axis with the CXCR4 inhibitor AMD3100, the preferential homing pattern of prostate cancer cells to osteoblast-rich bone surfaces was disrupted. In this study, we map the location of prostate cancer cells that home to endocortical regions in bone and our data demonstrate that homing of prostate cancer cells is associated with the presence and activity of osteoblast lineage cells, and suggest that therapies targeting osteoblast niches should be considered to prevent development of incurable prostate cancer bone metastases.
Introduction
Prostate cancer is the second most commonly diagnosed cancer in men and the sixth leading cause of cancer death globally (1) . In economically developed countries, prostate cancer is second only to lung cancer as the most frequent cancer and has the third highest mortality rate (1) . Although patients with prostate cancer have a relatively slowly growing primary tumour, which can be eradicated by current treatments, it is the presence of metastases that results in significant disease morbidity and mortality.
Around 90% patients with metastases have incurable bone metastases (2) , often associated with intractable bone pain, pathological fractures and decreased quality of life. Our understanding of the specific mechanism responsible for development of prostate cancer bone metastasis remains incomplete. As the preferred metastatic site, bone provides a supportive a microenvironment or 'niche' where prostate cancer cells can reside, survive and eventually grow in accordance with Paget's century old 'seed and soil' hypothesis (3, 4) . Recent studies using murine models and xenografted human prostate cancer cell lines have shown that prostate cancer cells target haemopoietic stem cell (HSC) niches and compete with HSCs to facilitate the establishment of bone metastases (5, 6) . The mobilization and proliferation of HSCs is suggested to be supported by the vascular niche, while the endosteal niche (including osteoblasts) maintains HSCs as a quiescent or reserve population (6) (7) (8) . Osteoblasts are suggested to fulfil this task via interacting with HSCs through sets of surface molecules, including Tie2/Angiopoietin-1 (Ang-1), Jagged1/Notch1, N-Cadherin and CXCR4/CXCL12 (5, (9) (10) (11) (12) (13) (14) (15) . In the case of the latter, CXCR4 is expressed by prostate cancer cells and CXCL12 by osteoblasts. This CXCR4/CXCL12 axis is considered to be a key component in the homing, adhesion, and survival of prostate cancer cells in bone (5, (16) (17) (18) (19) (20) (21) .
Given that the distribution of the osteoblast lineage cells is not uniform within the bone, it is likely that HSC niches are not uniformly located across the bone marrow.
In the mouse tibia, this topographical variation is more obvious on the endocortical surfaces than in the trabecular regions. This is due to skeletal response to mechanical loading and the consequent nature of bone resorption and formation required for bone modelling, in which osteoblastic bone formation predominantly occurs on lateral endocortical bone surfaces whereas osteoclastic resorption is found predominantly on medial endocortical bone surfaces (22) . In this study, we hypothesized that the prostate cancer cells homing to the bone marrow should have a similar spatial distribution pattern as the HSC osteoblast niches. We performed a series of experiments to test this hypothesis by mapping the early homing of human prostate cancer cells into the mouse tibia in a xenograph model, using a unique combination of two-photon microscopy and bone histomorphometry. We also tested whether the distribution pattern of prostate cancer cells in bone could be altered by disrupting the CXCR4/CXCL12 axis involved in cancer cell homing. These studies provide the first direct evidence that during the very early stages of bone metastasis, cancer cells locate to the areas of bone with the highest number of osteoblast lineage cells and that these cells play a significant role in establishing a foothold for prostate cancer cells metastases in bone, possibly via CXCR4/CXCL12 axis.
Materials and Methods

Mice
Six-week-old male BALB/cAnNCrl immunocompromised (athymic nude) mice (Charles River, Kent, UK) were used as a model to examine prostate cancer cells distribution in bone. Transgenic mice engineered to express GFP under the control of type 1 collagen promoter (pOBCol2.3GFPemd) (23) In the dynamic bone histomorphometry studies, alizarin complexone labels were detected using a 543nm laser while bone and calcein labels were detected using the 900nm two-photon laser. Within 300 m of endocortical bone surfaces (one third of the cross-sectional diameter of bone marrow cavity in tibial metaphysis region), the number of cancer cells, the intensity of DiD labelling of cancer cells, and minimal distance from centroid of these cells to the lateral and medial endocortical bone surfaces, were then analysed using the Volocity 3D Image Analysis software 6.01
(PerkinElmer, Cambridge, UK).
Bone histomorphometry
The tibiae were dissected and fixed in 10% buffered formaldehyde, decalcified in 14.3%
EDTA, and then embedded in paraffin wax so that a complete longitudinal section could be cut. Sections were cut longitudinally at 3µm thickness and tartrate-resistant acid phosphatase (TRAP) stained as described previously (24) . The number of osteoblasts (N.Ob/B.Pm), osteoblast surface (Ob.Pm/B.Pm), the number of osteoclasts (N.Oc/B.Pm), and the osteoclast surface (Oc.Pm/B.Pm) were determined on a 1.5mm length of lateral and medial endocortical surfaces, using a DMRB microscope (Leica Microsystems, Wetzlar, Germany). All histomorphometric parameters were based on the report of the ASBMR Histomorphometry nomenclature (25) and were obtained using the Osteomeasure bone histomorphometry software (OsteoMetrics, Inc. Decatur, GA, USA).
Dynamic bone histomorphometry
To determine the different bone remodelling activities on lateral and medial endocortical bone surfaces, mice were injected intraperitoneally with Alizarin complexone (20mg/kg, Sigma-Aldrich Ltd, Poole, Dorset, UK) on day 0 and calcein (30 mg/kg, Sigma-Aldrich Ltd, Poole, Dorset, UK) on day 6, post cancer cell injection.
The mice were euthanized 7 days post tumour injection and the tibiae were then dissected and fixed in 70% ethanol, followed by embedding into LR White resin (Taab Laboratory Equipment Ltd, Reading, Berkshire, UK). Sections were cut at 10µm using a Leica Microsystems Microtome. Mineral apposition rates (MAR), mineralizing surface (MS), and the bone formation rates (BFR/BS) were obtained using a BioQuant Osteo image analysis system (BIOQUANT, Nashville, TN, USA).
Mobilization of bone homing cancer cells by a CXCR4 inhibitor
Six-week old male Balb/c nude mice were injected (i.c.) with 1×10 5 DiD labelled PC3-NW1 cells. Seven days after cancer cell injection, animals were subject to 5 days of treatment with the CXCR4 inhibitor AMD3100 (Marketed as Plerixafor) (5mg/kg, daily intraperitoneal injection in 100 L PBS) (Sigma Aldrich Co Ltd, Poole, UK) or PBS control ( Figure 5A ). Animals were then euthanized and the distributions of DiD labelled PC3 NW1 cells were examined in the tibias by two-photon microscopy ex vivo and analyzed with the Volocity 3D Image analysis software.
Statistical analysis
All data are expressed as mean ± SEM. Statistical significance was tested for twotailed paired or unpaired t test as appropriate with Prism 5 software (GraphPad, La Jolla, CA, USA). p< 0.05 was considered to be significant (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p<0.0001)
Results
Spatial distribution of PC3-NW1 prostate cancer cells homing to mouse tibiae
Seven days after injection of DiD labelled PC3-NW1 cells, mice were euthanized and tibiae were collected and processed for two-photon microscopy. The DiD labelled Figure 1E ). The intensity of DiD staining of prostate cancer cells reach a peak value on day 7 and then started to slowly decline ( Figure 1F ), indicating the homed cancer cells did not start growth within the first 7 days after injection. These data suggest that there is a particular distribution pattern of prostate cancer cells localised in bone, including close proximity to bone surfaces and preferential homing to the lateral endocortical compared to medial surfaces. Bone formation differs between lateral and medial endocortical bone surfaces
To examine the different bone formation activities on lateral and medial endocortical bone surfaces, mice were injected with Alizarin complexone on day 0 and calcein on day 6 after cancer cell injection. Two distinctive alizarin and calcein labels on the proximal endocortical surfaces of tibiae were visualized using two-photon microscopy ( Figure 3A) . The double labels were imaged and quantified using the BioQuant Osteo image analysis system to calculate the bone formation related parameters including mineralizing surface (MS), mineral apposition rate (MAR), and the bone formation rate (BFR/BS) ( Figure 3B ). All these parameters showed significantly higher values on the lateral compared to the medial endocortical surfaces, including 48% higher MS 
Effects of disruption of the CXCR4/CXCL12 axis on cancer cell distribution
Disruption of the CXCR4/CXCL12 axis with CXCR4 inhibitor (AMD3100) has been shown to mobilize prostate cancer cells that had homed to the bone microenvironment in a xenograft model (5) . To determine whether disruption of the CXCR4/CXCL12 axis would change the spatial distribution of cancer cells in bone in our models, animals received five daily injections of AMD3100, starting seven days after cancer cell injection ( Figure 5A ). Two-photon microscope imaging showed the presence of DiD labelled PC3-NW1 cells in both the AMD3100 treated and the vehicle group ( Figure 5B Figure 5D ). These data suggested that the spatial distribution of prostate cancer cells in bone could be altered as a result of disruption of CXCR4/CXCL12 axis.
Discussion
Prostate cancer cells have been shown to home to the endosteal niche of the metaphysis region of the long bones prior to development of bone metastases (5, 6) . As the distribution of osteoblast lineage cells is not uniform within the metaphysis regions, we hypothesized that the spatial distribution of prostate cancer cells homed to bone should follow a pattern that correlates with the distribution of niches, and that the location of cancer cells would be altered if the linkage to their bone niches were disrupted.
In this study, we used three prostate cancer cell lines as metastatic models to investigate the bone homing process after i.c. inoculation into immunocompromised mice. Using fluorescent dye DiD as a marker to monitor the proliferation of prostate cancer cell in vivo (26) , cancer cells were shown to maintain DiD fluorescence at a high level up to 7 days after injection, suggesting that no significant proliferation had started by this time point. This result demonstrated that inoculated cancer cells were still involved in the process of homing rather than growth within this period, which is consistent with previous studies using different models (27, 28) . Our results indicated that prostate cancer cells preferentially home to the osteoblast-rich lateral endocortical bone surface of the tibiae where bone formation rates are higher, rather than to the medial side with fewer osteoblasts and lower bone formation rates. These 
, cancer cells were located less than 40 m away from closest bone surface, suggesting that they are around one to two cell diameters away from the bone. It is likely that the cells between the bone surface and the cancer cell are of osteoblast lineage, as has been shown in a previous study (5) . Indeed, further investigation of the spatial distribution of prostate cancer cells within bone marrow showed that there was at least All stages are likely to be increased in areas where mature osteoblasts are abundant.
To test the hypothesis that osteoblast lineage cells are directly involved in the distribution pattern of homed prostate cancer cells, AMD3100 was used to disrupt the binding of CXCL12 on osteoblasts to its receptor CXCR4 expressed by prostate cancer cells and mobilize these cancer cells from their homing niches. This is consistent with a previous study (5) . After 5 days of treatment with AMD3100, the pattern of predominant homing of prostate cancer cells to lateral bone surfaces had disappeared. At the same time, tumour cell mobilisation from the niche was suggested by an increase in the distance to the nearest bone surface following treatment with AMD3100 compared to control. As osteoblasts are proposed to be a major source of CXCL12 in the bone marrow and serve as docking sites for HSCs and prostate cancer cells (5, 10, 33, 34) , this finding is at least partially supported in our study, which suggests that the spatial distribution of prostate cancer cells in bone marrow correlates with the location of the osteoblastic niche.
Our data suggested that AMD3100 treatment did not significantly decrease the number of prostate cancer cells in bone, but altered the distribution of cancer cells such that they were further away from bone surfaces (≥50 m). This observation differs from a previous study, in which Shiozawa et al reported that the same AMD3100 treatment regimen mobilized prostate cancer cells from bone niches back into circulation 24 hrs after treatment (20) . This discrepancy could be due to either we captured the transition towards the vasculature of mobilized prostate cancer cells or their re-entering the niche in our study, or CXCR4/CXCL12 not being the single interaction responsible for homing of prostate cancer cells. Therefore, disruption of this single interaction may only lead to partial mobilization of homed prostate cancer cells. For example, it was reported that CXCR7 is also expressed by prostate cancer cells as an alternative receptor for CXCL12 (6, 19) , while AMD3100
can also bind to CXCR7 as an allosteric agonist, opposite to its antagonistic nature to CXCR4 (35) . In addition, other CXCL12-independent mechanisms have also been suggested to be involved in prostate cancer cells and HSCs homing niche competition process, such as annexin II (Anxa2), c-kit, and vascular cell adhesion molecule-1 (VCAM-1)/integrins 4 1 (also known as the very late antigen-4, VLA-4) (36) (37) (38) (39) (40) (41) (42) .
While it is likely that location of tumour cells to specific niches is mediated by direct interactions between cells/matrices, it also possible that soluble growth factors expressed by osteoblasts, such as vascular endothelial growth factor (VEGF), BMPs and insulin-like growth factors (IGFs) (43) (44) (45) (46) (47) , play important roles in the homing process. Such factors could induce tumour associated angiogenesis, differentiation/growth arrest but most importantly allow migration/survival of cancer cells in osteoblastrich environments. All these mechanisms may help the prostate cancer cells stay in close proximity to bone marrow microenvironment, even after mobilized by CXCR4 inhibitors.
Vascular and/or perivascular niches may also contribute to this spatial distribution of homed cancer cells. Metastatic foci have often been observed in regions with abundant sinusoids, which are a main form of vascular supply in bone marrow rather than capillary beds (48) . Cancer cells have been shown to be rapidly engrafted into the perivascular regions around the bone marrow sinusoidal network (49) (50) (51) . This is thought to be due to the high expression of adhesive proteins including E-selection, Pselection, intercellular adhesion molecule (ICAM-1) and VCAM-1 by the endothelial cells of the bone sinusoids (48, 50) . Indeed, our data underline these findings and Taken together, this is the first study to provide direct evidence identifying the locations of osteoblast-rich niches to which the prostate cancer cells home in the early stage of bone metastasis. In patients, metastatic hotspots include sites with high bone turnover such as vertebral bodies and metaphysis regions of long bone (52) . Indeed, this has been highlighted by several successful clinical trials applying bone-homing radiopharmaceuticals (strontium-89, samarium, and rhenium) to sites of increased osteoblast activity (53) . Whilst these trials are focused on targeting osteosclerotic cancer induced bone diseases where metastatic growth is advanced, our study suggest that early targeting of areas of high bone turnover could inhibit cancer cell homing.
Interestingly, early use of bisphosphonate inhibits the initiation of bone metastasis in both clinical trials and xenograft models, possibly via disruption of the interactions between osteoblasts and cancer cells (54, 55) . Targeting the osteoblast abundant regions, where a higher frequency of prostate cancer cells could be expected, may be a useful strategy for preventing bone metastases. In addition, our study also underlined the therapeutic potential to use HSC niche mobilization agents (such as AMD3100) in conjunction with conventional chemotherapy to both eliminate the chemotherapy resistant dormant prostate cancer cells and target the growing metastasis at the same time (16) . 
